An Early Look at a Combined mRNA Vaccine Against Seasonal Influenza and COVID-19

This mRNA-based multicomponent vaccine triggered an immune response comparable to that seen for the vaccines given separately.

Given that seasonal influenza and COVID-19 vaccines require repeated administration, a combined vaccine might improve both coverage and resource utilization. In an industry-sponsored phase 1/2 study, investigators randomized adults to receive one dose of multicomponent mRNA influenza and COVID-19 vaccine (with different ratios of mRNAs encoding SARS-CoV-2/influenza hemagglutinin), licensed influenza vaccine, or licensed COVID-19 (bivalent mRNA-1273) vaccine.

In all, 1216 adults were enrolled (595 aged ≥65 and 621 aged 18–64). Most participants had previously received influenza vaccine (68%) and bivalent mRNA-1273 (55%). At 29 days after vaccine receipt, immune responses to the 4 influenza antigens contained in the vaccine were comparable acr…

Reviewing Author

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

An Early Look at a Combined mRNA Vaccine Against Seasonal Influenza and COVID-19

Topics

Reviewing Author